W
Waly Dioh
Researcher at University of Paris
Publications - 12
Citations - 181
Waly Dioh is an academic researcher from University of Paris. The author has contributed to research in topics: 20-Hydroxyecdysone & Excretion. The author has an hindex of 4, co-authored 12 publications receiving 112 citations.
Papers
More filters
Journal ArticleDOI
Quinoa extract enriched in 20-hydroxyecdysone protects mice from diet-induced obesity and modulates adipokines expression.
Anne-Sophie Foucault,Véronique Mathé,Véronique Mathé,René Lafont,Patrick C. Even,Patrick C. Even,Waly Dioh,Stanislas Veillet,Daniel Tomé,Daniel Tomé,Jean-François Huneau,Jean-François Huneau,Dominique Hermier,Dominique Hermier,Annie Quignard-Boulangé,Annie Quignard-Boulangé +15 more
TL;DR: This study indicates that quinoa extract enriched in 20E supplementation has an antiobesity activity in vivo and could be used as a nutritional supplement for the prevention and treatment of obesity and obesity‐associated disorders.
Journal ArticleDOI
Quinoa extract enriched in 20-hydroxyecdysone affects energy homeostasis and intestinal fat absorption in mice fed a high-fat diet
Anne-Sophie Foucault,Patrick C. Even,René Lafont,Waly Dioh,Stanislas Veillet,Daniel Tomé,Jean-François Huneau,Dominique Hermier,Annie Quignard-Boulangé,Annie Quignard-Boulangé +9 more
TL;DR: The study indicates that anti-obesity effect of QE can be explained by a global increase in energy expenditure, a shift in glucose metabolism towards oxidation to the detriment of lipogenesis and a decrease in dietary lipid absorption leading to reduced dietary lipid storage in adipose tissue.
Journal ArticleDOI
20-Hydroxyecdysone, from Plant Extracts to Clinical Use: Therapeutic Potential for the Treatment of Neuromuscular, Cardio-Metabolic and Respiratory Diseases
TL;DR: There is growing interest in the pharmaceutical and medical applications of 20-hydroxyecdysone (20E), a polyhydroxylated steroid which naturally occurs in low but very significant amounts in invertebrates, and in certain plant species, where it is believed to contribute to the deterrence of invertebrate predators as mentioned in this paper.
Journal ArticleDOI
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Waly Dioh,M. Chabane,C. Tourette,A Azbekyan,C Morelot-Panzini,L A Hajjar,M Lins,G B Nair,Tony Whitehouse,J Mariani,Mathilde Latil,Serge Camelo,René Lafont,Pierre J. Dilda,Stanislas Veillet,S. Agus +15 more
TL;DR: Biophytis et al. as mentioned in this paper developed BIO101 (20-hydroxyecdysone, a Mas receptor activator) as a new treatment option for managing patients with SARS-CoV-2 infection at the severe stage.
Posted ContentDOI
20-Hydroxyecdysone activates the protective arm of the renin angiotensin system via Mas receptor
Rencé Lafont,Sophie Raynal,Maria Serova,Blaise Didry-Barca,Louis Guibout,Mathilde Latil,Pierre J. Dilda,Waly Dioh,Stanislas Veillet +8 more
TL;DR: The possibility to activate the Mas receptor with a safe steroid molecule is consistent with the pleiotropic pharmacological effects of ecdysteroids in mammals and indeed this mechanism may explain the close similarity between angiotensin-(1-7) and 20E effects.